Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Actavis Plc (NY: )

N/A UNCHANGED
Last Price Updated: Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Actavis Plc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Emergency Medicine of the Future Demonstrated at ACEP15
"InnovatED" to Feature Emergency Simulations and Next Generation Technology 
From PR Newswire
Allergan Anti-Infective Portfolio Highlighted in 13 Abstracts at IDWeek 2015
Allergan plc (NYSE: ACT) today announced that its infectious disease portfolio will be featured in 13 abstracts highlighting data at IDWeek 2015, which takes place from October 7-11, 2015, in San... 
From PR Newswire
Allergan Reports Exceptional Second Quarter 2015 Performance with 116% Increase in Net Revenue to $5.76 Billion and 29% Growth in Non-GAAP EPS to $4.41
-- Adjusted EBITDA Increases 203% to $2.6 Billion in Second Quarter 2015 -- 
From PR Newswire
Eastman Receives Top Honor for College and Career Readiness
Tags Science engineering steam
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Actavis Announces FDA Approval of NATRELLE INSPIRA™ Round Gel-Filled Textured Breast Implants
- Company now offers the industry's widest range of breast implant options - 
From PR Newswire
Actavis to Present at the Goldman Sachs 36th Annual Global Healthcare Conference
From PR Newswire
Actavis And Perrigo Receive FDA Approval Of Guaifenesin/Pseudoephedrine, The Store Brand Equivalent To Mucinex® D Tablets
From PR Newswire
Actavis Affirms Commitment To Advancing Antibiotic Stewardship At White House Forum
- Actavis Commitment Extends to Fostering Collaborative Research Efforts, Gathering Unique Epidemiological Information and Generating Real-World Data to Demonstrate the Effects of Stewardship on... 
From PR Newswire
Actavis Completes Acquisition of Auden Mckenzie
From PR Newswire
Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults
-First in class treatment for IBS-D treats hallmark symptoms of IBS-D; abdominal pain and diarrhea 
From PR Newswire
Infectious Disease Experts, Scientists and Clinicians Join Forces on SHARE ID™ to Accelerate the Battle Against Antibiotic-resistant Infections
- Initiative Supported by Actavis Aims to Help Advance Evidence-Based Treatment Practices Using Unique Data-Sharing Platform - 
From PR Newswire
Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR
From PR Newswire
Actavis to Present at Bernstein's Thirty-First Annual Strategic Decisions Conference 2015
From PR Newswire
Actavis Launches NAMZARIC™ (memantine hydrochloride extended-release and donepezil hydrochloride), a Fixed-Dose Combination Therapy for the Treatment of Moderate to Severe Alzheimer's Disease
- NAMZARIC is now available across the United States - 
From PR Newswire
Actavis to Present at UBS Global Healthcare Conference 2015
From PR Newswire
Actavis Reports Exceptional Performance in First Quarter 2015 with 59% Increase in Net Revenue to $4.2 Billion and 23% Growth in Non-GAAP EPS to $4.30
-- Adjusted EBITDA Increases 107% to $1.8 Billion in First Quarter 2015 -- 
From PR Newswire
IBS in America: American Gastroenterological Association Initiates Comprehensive Survey of Patients and Physicians
Survey aims to shed light on irritable bowel syndrome and drive better communication between doctors and their patients 
From PR Newswire
Actavis to Re-launch Generic Pulmicort RESPULES® Following Favorable Appeals Court Ruling
From PR Newswire
Morning Briefing on Pharma Equities -- Mylan, Actavis, Zoetis, Horizon Pharma, and Medicines
From PR Newswire
Actavis and Medicines360 Announce Publication of ACCESS IUS Efficacy and Safety Study of LILETTA™ (Levonorgestrel-Releasing Intrauterine System) 52 mg in Contraception
- Largest Phase 3 Pivotal Hormonal IUD Trial Conducted Exclusively in U.S. Supports FDA Approval of LILETTA for Women - 
From PR Newswire
Actavis Announces Topline Phase 3 Clinical Trial Results for Single-Dose DALVANCE® (dalbavancin) in the Treatment of ABSSSI
---DUR001-303 Study Meets Primary & Secondary Endpoints--- 
From PR Newswire
Cipher Pharmaceuticals announces outcome of Markman hearing in patent infringement suit for Absorica®
From PR Newswire
Actavis Launches AVYCAZ™ (Ceftazidime-Avibactam) Anti-Infective In U.S.
- Treatment for Adult Patients with Complicated Intra-abdominal infections (cIAI) and Complicated Urinary Tract Infections (cUTI) - 
From PR Newswire
Actavis Announces Retirement of Charles M. Mayr
From PR Newswire
Actavis Announces FDA Approval of Expanded Label for BOTOX® (OnabotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Adults
Label updates include addition of two thumb flexor muscles and increased maximum cumulative dose 
From PR Newswire
Actavis to Host First Quarter 2015 Earnings Conference Call and Webcast
From PR Newswire
Actavis and Medicines360 Announce U.S. Availability of LILETTA™ (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Three Years
-LILETTA™ Now Available in Doctors' Offices and Through Public Health Clinics- 
From PR Newswire
Actavis and Medicines360 Announce U.S. Availability of LILETTA™ (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Three Years
-- LILETTA™ Now Available in Doctors' Offices and Through Public Health Clinics -- 
From PR Newswire
Rhythm Initiates Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis
-- Actavis has Option to Purchase Rhythm subsidiary, Rhythm Pharmaceuticals, Inc., Upon Successful Completion of this Study -- 
From PR Newswire
Rhythm Initiates Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis
-- Actavis has option to purchase Rhythm subsidiary, Rhythm Pharmaceuticals, Inc., upon successful completion of this study -- 
From PR Newswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.